FindTrial
Sign In

Observational study of COVID-19 prophylactic antibody administration in immunosuppressed patients

Observational study of COVID-19 prophylactic antibody (Tixagevimab-Cilgavimab) administration in immunosuppressed patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007617
Enrollment
100
Registered
2022-08-05
Start date
2022-08-16
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ulsan Univeristy Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 19 years of age or older 2) Weight 40kg or more 3) If there is no confirmed history of COVID-19 within the last 7 days as of the scheduled administration date of Evusheld 4) Lymphoma (morbidity code: C81, C82, C83, C84, C85, C86), multiple myeloma (C90), acute leukemia (C92, C95) patients who have treated with immunosuppressive agents or chemotherapy within 2 months 5) Patients who have received an allogeneic hematopoietic stem cell transplant within 4 months 6) Patients who have received autologous hematopoietic stem cell transplantation within 2 months 7) Those who voluntarily decided to participate in this study and gave their written consent

Exclusion criteria

Exclusion criteria: 1) Contraindications to Evusheld administration 2) denial of consent

Design outcomes

Primary

MeasureTime frame
serious adverse reactions—

Secondary

MeasureTime frame
Antibody detection rate evaluation—

Countries

Korea, Republic of

Contacts

Public ContactYoo Jin Lee

Ulsan Univeristy Hospital

yjleeH@UUH.ulsan.kr+82-52-250-8874

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 8, 2026